Roche’s oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits - Fierce Biotech
Roche’s oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits - Fierce Biotech
Contenu indisponible. Consultez la source originale.